Login to Your Account

Clinic Roundup

Monday, March 21, 2011
Polaris Group, of San Diego, enrolled the first patient in a Phase II trial of ADI-PEG 20 (pegylated arginine deiminase), its enzyme-based treatment for malignant mesothelioma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription